{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:26:59Z","timestamp":1794500819894,"version":"4.9.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>Buprenorphine use in pregnancy and postpartum for individuals with opioid use disorder (OUD) decreases maternal and fetal morbidity and mortality. Extended-release buprenorphine overcomes barriers to sublingual buprenorphine, but very limited data are available regarding use in the perinatal period. We aimed to describe extended-release buprenorphine uptake and associated recovery and pregnancy outcomes in a case series of 15 pregnant and postpartum individuals with OUD. Reasons for extended-release buprenorphine initiation included nausea, burdensome multiple daily dosing of sublingual buprenorphine, and persistent cravings. Postinitiation, all patients demonstrated increased buprenorphine adherence, total cessation of nonprescribed opioids, and a reduction in other substance use. There were no identified maternal or neonatal side effects. Our data provide early evidence for safety, adherence, and reduced substance use among perinatal patients with OUD treated with extended-release buprenorphine.<\/jats:p>","DOI":"10.1097\/aog.0000000000006091","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T21:00:42Z","timestamp":1760648442000},"page":"565-568","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Extended-Release Buprenorphine for Treatment of Opioid Use Disorder During Pregnancy and Postpartum"],"prefix":"10.1097","volume":"147","author":[{"given":"Nia","family":"Bhadra-Heintz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Schapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Roder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Carney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Chertok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Lowenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"R1-20261112","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/AOG.0000000000004649","article-title":"Pregnancy-associated deaths due to drugs, suicide, and homicide in the United States, 2010\u20132019","volume":"139","author":"Margerison","year":"2022","journal-title":"Obstet Gynecol"},{"key":"R2-20261112","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/AOG.0000000000002734","article-title":"Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts","volume":"132","author":"Schiff","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R3-20261112","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v12i8.5736","article-title":"Current research on opioid use disorder (OUD) in pregnancy with emphasis on medication-assisted treatment (MAT)","volume":"12","author":"Chokshi","year":"2024","journal-title":"Med Res Arch"},{"key":"R4-20261112","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1080\/08897077.2021.1949664","article-title":"Disparities in receipt of medications for opioid use disorder among pregnant women","volume":"43","author":"Henkhaus","year":"2022","journal-title":"Subst Abus"},{"key":"R5-20261112","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1111\/add.15582","article-title":"Outcomes associated with the use of medications for opioid use disorder during pregnancy","volume":"116","author":"Krans","year":"2021","journal-title":"Addiction"},{"key":"R7-20261112","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"key":"R8-20261112","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0278-6915(02)00300-9","article-title":"Developmental toxicity of N-methyl-2-pyrrolidone in rats following inhalation exposure","volume":"41","author":"Saillenfait","year":"2003","journal-title":"Food Chem Toxicol"},{"key":"R9-20261112","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/ajad.13518","article-title":"Extended-release buprenorphine in pregnancy","volume":"33","author":"Hubbell","year":"2024","journal-title":"Am J Addict"},{"key":"R10-20261112","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/AOG.0000000000004126","article-title":"Subcutaneous buprenorphine extended-release use among pregnant and postpartum women","volume":"136","author":"Cleary","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R11-20261112","doi-asserted-by":"crossref","first-page":"110","DOI":"10.14740\/jcgo919","article-title":"What to expect with pregnant or postpartum prescribing of extended-release buprenorphine (CAM2038)","volume":"12","author":"Lofwall","year":"2023","journal-title":"J Clin Gynecol Obstet"},{"key":"R12-20261112","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/ADM.0000000000000835","article-title":"The use of once-monthly injectable buprenorphine for the treatment of opioid use disorder in postpartum women: a case series","volume":"15","author":"Shadowen","year":"2021","journal-title":"J Addict Med"},{"key":"R13-20261112","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/AOG.0000000000005319","article-title":"Buprenorphine extended-release treatment for opioid use disorder in the postpartum period","volume":"142","author":"Galati","year":"2023","journal-title":"Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:00:17Z","timestamp":1794499217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006091","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"2025-06-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}